JP7227138B2 - 骨標的抗体 - Google Patents

骨標的抗体 Download PDF

Info

Publication number
JP7227138B2
JP7227138B2 JP2019539277A JP2019539277A JP7227138B2 JP 7227138 B2 JP7227138 B2 JP 7227138B2 JP 2019539277 A JP2019539277 A JP 2019539277A JP 2019539277 A JP2019539277 A JP 2019539277A JP 7227138 B2 JP7227138 B2 JP 7227138B2
Authority
JP
Japan
Prior art keywords
antibody
mab1
seq
antigen
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019539277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505919A (ja
JP2020505919A5 (enExample
Inventor
ファーウェイ・チウ
サングヘー・パーク
ジェームズ・ステファノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2020505919A publication Critical patent/JP2020505919A/ja
Publication of JP2020505919A5 publication Critical patent/JP2020505919A5/ja
Priority to JP2023017271A priority Critical patent/JP7597836B2/ja
Application granted granted Critical
Publication of JP7227138B2 publication Critical patent/JP7227138B2/ja
Priority to JP2024205967A priority patent/JP2025028981A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019539277A 2017-01-20 2018-01-19 骨標的抗体 Active JP7227138B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023017271A JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
US62/448,763 2017-01-20
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017271A Division JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体

Publications (3)

Publication Number Publication Date
JP2020505919A JP2020505919A (ja) 2020-02-27
JP2020505919A5 JP2020505919A5 (enExample) 2021-02-18
JP7227138B2 true JP7227138B2 (ja) 2023-02-21

Family

ID=61581744

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019539277A Active JP7227138B2 (ja) 2017-01-20 2018-01-19 骨標的抗体
JP2023017271A Active JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A Pending JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023017271A Active JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A Pending JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Country Status (17)

Country Link
US (3) US10844115B2 (enExample)
EP (1) EP3571226A2 (enExample)
JP (3) JP7227138B2 (enExample)
KR (3) KR102613463B1 (enExample)
CN (2) CN111032690B (enExample)
AR (1) AR110755A1 (enExample)
AU (1) AU2018210270A1 (enExample)
BR (1) BR112019013986A2 (enExample)
CA (1) CA3050884A1 (enExample)
IL (2) IL268114B2 (enExample)
MX (2) MX2019008549A (enExample)
MY (2) MY207919A (enExample)
SG (1) SG11201906663VA (enExample)
TW (3) TWI832600B (enExample)
UY (1) UY37576A (enExample)
WO (1) WO2018136698A2 (enExample)
ZA (1) ZA201907673B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023058590A (ja) * 2017-01-20 2023-04-25 ジェンザイム・コーポレーション 骨標的抗体

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033614A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. Tgf-.beta. antagonist conjugates
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US20210155708A1 (en) * 2018-07-10 2021-05-27 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
EP3884066A2 (en) * 2018-11-19 2021-09-29 Biocartis NV Enhanced detection of low-copy-number nucleic acids in an integrated workflow
AU2022269615A1 (en) 2021-05-07 2023-12-21 Baylor College Of Medicine Treatment of moderate-to-severe osteogenesis imperfecta
CA3226401A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy
CA3237245A1 (en) * 2021-11-01 2023-05-04 Genzyme Corporation Treatment of osteogenesis imperfecta
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506028A (ja) 1999-08-02 2003-02-18 エフ． ホフマン−ラ ロシュ アーゲー キメラポリペプチド、その製造方法、およびその使用
JP2008529503A (ja) 2005-02-08 2008-08-07 ジェンザイム・コーポレイション ＴＧＦβに対する抗体
JP2011509084A (ja) 2008-01-03 2011-03-24 ザ スクリプス リサーチ インスティチュート モジュラー認識ドメインを介してターゲティングする抗体
JP2012513377A (ja) 2008-12-22 2012-06-14 ノヴォ・ノルディスク・アー／エス 組織因子経路阻害因子に対する抗体
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
JP2014519524A (ja) 2011-06-13 2014-08-14 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
JP2015502336A (ja) 2011-10-19 2015-01-22 アレクシオン ファーマ ホールディング アルカリホスファターゼ及び／又はナトリウム利尿ペプチドを含む組成物、並びにそれを使用する方法
JP2015519355A (ja) 2012-05-31 2015-07-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｔｌｒ３結合剤
JP2016519093A (ja) 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
WO2004098637A1 (en) 2003-04-30 2004-11-18 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
WO2007076391A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2908913B1 (en) 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
KR102630750B1 (ko) 2013-12-17 2024-01-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) * 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
JP6901400B2 (ja) 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
NZ735820A (en) 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3344660B1 (en) * 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506028A (ja) 1999-08-02 2003-02-18 エフ． ホフマン−ラ ロシュ アーゲー キメラポリペプチド、その製造方法、およびその使用
JP2008529503A (ja) 2005-02-08 2008-08-07 ジェンザイム・コーポレイション ＴＧＦβに対する抗体
JP2011509084A (ja) 2008-01-03 2011-03-24 ザ スクリプス リサーチ インスティチュート モジュラー認識ドメインを介してターゲティングする抗体
JP2012513377A (ja) 2008-12-22 2012-06-14 ノヴォ・ノルディスク・アー／エス 組織因子経路阻害因子に対する抗体
JP2012524818A (ja) 2009-04-24 2012-10-18 バンダービルト ユニバーシティ 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法
JP2014519524A (ja) 2011-06-13 2014-08-14 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
JP2015502336A (ja) 2011-10-19 2015-01-22 アレクシオン ファーマ ホールディング アルカリホスファターゼ及び／又はナトリウム利尿ペプチドを含む組成物、並びにそれを使用する方法
JP2015519355A (ja) 2012-05-31 2015-07-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｔｌｒ３結合剤
JP2016519093A (ja) 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023058590A (ja) * 2017-01-20 2023-04-25 ジェンザイム・コーポレーション 骨標的抗体
JP7597836B2 (ja) 2017-01-20 2024-12-10 ジェンザイム・コーポレーション 骨標的抗体

Also Published As

Publication number Publication date
KR20190105236A (ko) 2019-09-16
IL317592A (en) 2025-02-01
MY207919A (en) 2025-03-27
CN111032690A (zh) 2020-04-17
ZA201907673B (en) 2021-05-26
WO2018136698A2 (en) 2018-07-26
MX2019008549A (es) 2019-09-11
KR20250012197A (ko) 2025-01-23
MX2022008073A (es) 2022-07-27
TWI832600B (zh) 2024-02-11
KR102613463B1 (ko) 2023-12-15
JP7597836B2 (ja) 2024-12-10
KR102755284B1 (ko) 2025-01-22
AU2018210270A1 (en) 2019-09-05
TWI788321B (zh) 2023-01-01
TW202421659A (zh) 2024-06-01
CN111032690B (zh) 2024-03-26
MY194819A (en) 2022-12-17
CA3050884A1 (en) 2018-07-26
WO2018136698A3 (en) 2018-08-30
EP3571226A2 (en) 2019-11-27
SG11201906663VA (en) 2019-08-27
IL268114B2 (en) 2025-05-01
IL268114B1 (en) 2025-01-01
US20210163584A1 (en) 2021-06-03
IL268114A (en) 2019-09-26
TW201839013A (zh) 2018-11-01
US20180208650A1 (en) 2018-07-26
JP2023058590A (ja) 2023-04-25
AR110755A1 (es) 2019-05-02
US12098194B2 (en) 2024-09-24
TW202330597A (zh) 2023-08-01
KR20230172039A (ko) 2023-12-21
US20250074975A1 (en) 2025-03-06
JP2020505919A (ja) 2020-02-27
BR112019013986A2 (pt) 2020-03-03
UY37576A (es) 2018-10-31
CN118121696A (zh) 2024-06-04
RU2019126026A (ru) 2021-02-20
US10844115B2 (en) 2020-11-24
RU2019126026A3 (enExample) 2021-11-09
JP2025028981A (ja) 2025-03-05

Similar Documents

Publication Publication Date Title
JP7597836B2 (ja) 骨標的抗体
ES3009519T3 (en) Il-15 and il-15ralpha sushi domain based conjugates
JP7279054B2 (ja) Ｅｄｂ標的化ｉｌ－１２組成物
US11623963B2 (en) Cysteine engineered antigen-binding molecules
CN110234355A (zh) 单体人IgG1 Fc和双特异性抗体
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
CN109496149B (zh) 抗体及其药物缀合物的制剂
TW202100557A (zh) 雙互補位ＦＲ-α抗體及免疫結合物
JP7458567B2 (ja) Ｃ－ｍｅｔ結合剤
JP2020532523A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
JP2020532543A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
EP3674316A1 (en) Multispecific binding proteins with mutant fab domains
RU2801206C2 (ru) Антитела, нацеливающиеся на костную ткань
JP2025527160A (ja) 多重特異性抗体およびその使用
CN120530135A (zh) 抗b7h3抗体和使用方法
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230209

R150 Certificate of patent or registration of utility model

Ref document number: 7227138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150